5-tert-butyl-3-cyclopropyl-1-methylindazole;5-tert-butyl-1-methyl-3-(1-methylpyrazol-4-yl)indazole
C31H40N6 — CID 158800089
Data last refreshed: (MolForge compound catalog, from PubChem)
About 5-tert-butyl-3-cyclopropyl-1-methylindazole;5-tert-butyl-1-methyl-3-(1-methylpyrazol-4-yl)indazole
5-tert-butyl-3-cyclopropyl-1-methylindazole;5-tert-butyl-1-methyl-3-(1-methylpyrazol-4-yl)indazole (PubChem CID 158800089) has the molecular formula C31H40N6 and a molecular weight of 496.70 g/mol. Its IUPAC name is 5-tert-butyl-3-cyclopropyl-1-methylindazole;5-tert-butyl-1-methyl-3-(1-methylpyrazol-4-yl)indazole.
Molecular Properties
| Compound Name | 5-tert-butyl-3-cyclopropyl-1-methylindazole;5-tert-butyl-1-methyl-3-(1-methylpyrazol-4-yl)indazole |
|---|---|
| PubChem CID | 158800089 |
| Molecular Formula | C31H40N6 |
| Molecular Weight | 496.70 g/mol |
| Exact Mass | 496.33 |
| IUPAC Name | 5-tert-butyl-3-cyclopropyl-1-methylindazole;5-tert-butyl-1-methyl-3-(1-methylpyrazol-4-yl)indazole |
| SMILES | Cn1cc(-c2nn(C)c3ccc(C(C)(C)C)cc23)cn1.Cn1nc(C2CC2)c2cc(C(C)(C)C)ccc21 |
| InChI | InChI=1S/C16H20N4.C15H20N2/c1-16(2,3)12-6-7-14-13(8-12)15(18-20(14)5)11-9-17-19(4)10-11;1-15(2,3)11-7-8-13-12(9-11)14(10-5-6-10)16-17(13)4/h6-10H,1-5H3;7-10H,5-6H2,1-4H3 |
| InChIKey | ITJIZTRTXZVXNU-UHFFFAOYSA-N |
| XLogP | 7.02 |
| TPSA | 53.46 Ų |
| H-Bond Donors | |
| H-Bond Acceptors | 6 |
| Rotatable Bonds | 2 |
| Heavy Atoms | 37 |
| Complexity | — |
Lipinski Rule of Five
1 violation
| Rule | Value |
|---|---|
| MW ≤ 500 | 496.70 |
| LogP ≤ 5 | 7.02 |
| H-Bond Donors ≤ 5 | 0 |
| H-Bond Acceptors ≤ 10 | 6 |
Frequently Asked Questions
Browse: Molecules A–Z · all molecules A–Z · drugs A–Z · protein targets A–Z.
Sources
- PubChem CID 158800089 — identifiers, structure, computed properties (public domain)
How this page is built: methodology · editorial policy & corrections.
For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.